US Proposes Investment Curbs on Chinese Biotech Firms
· World · Bloomberg, Financial Times
The Trump administration is seeking to restrict American investment in Chinese biotechnology companies, potentially complicating financial ties between the two nations. US drugmakers have increasingly partnered with Chinese firms for drug development and research capabilities. The proposed restrictions aim to address national security concerns regarding biotechnology supply chains and intellectual property. The exact timeline and scope of the proposed investment curbs remain under review by officials. No final regulatory framework has been officially enacted yet.
Why it matters
The proposed curbs directly affect US pharmaceutical companies and venture capital firms with financial stakes in Chinese biotech research, potentially reshaping cross-border drug development partnerships.
Read the original report — Bloomberg
Join us on Telegram
Breaking news the moment it lands. At 10,000 members we ship the Android app.